Anonymous User
Login / Registration

a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2021; 75(1): 51–54. doi: 10.48095/ccgh202151.

Rifaximin in therapy of inflammatory bowel disease

Milan Lukáš1

+ Affiliation

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users


1. DuPont HL. Review article: the antimicrobial effects of rifaximin on the gut microbio­nta. Aliment Pharmacol Ther 2016; 43 (Suppl 1): 3–10. doi: 10.1111/apt.13434.
2. Cheng J, Shah YM, Ma X et al. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther 2010; 335 (1): 32–41. doi: 10.1124/jpet.110.170225.
3. Prantera C, Lochs H, Campieri M et al. Antibio­tic treatment for Crohn’s disease: results of a multicentre, double blind, randomized, placebo controlled trial with rifaximin. Aliment Pharmacol Ther 2006; 23 (8): 1117–1125. doi: 10.1111/j.1365-2036.2006.02879.x.
4. Ďuricová D, Lukáš M, Bortlík M. Rifaximin v terapii Crohnovy nemoci. Výsledky studie GRACE 02. Ces a Slov Gastroent a Hepatol 2010; 64 (3): 31–36.
5. Prantera C, Lochs H, Grimaldi M et al. Rifaximin-extended intestinal release induces remis­sion in patients with moderately active Crohn’sdisease. Gastroenterology 2012; 142 (3): 473–481.doi: 10.1053/j.gastro.2011.11.032.
6. Townsend CM, Parker CE, MacDonald JK et al. Antibio­tics for induction and maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2019; 2 (2): CD012730. doi: 10.1002/ 14651858.CD012730.pub2.
7. D’Haens GR, Vermeire S, Van Aschee G et al. Therapy of metronidazole and azathioprine to prevent postoperative recurrence of Crohn’s disease: a controlled randomized trial. Gastroenterolohy 2008; 135 (4): 1123–1129. doi: 10.1053/j.gastro.2008.07.010.
8. Gionchetti P, Rizzello F, Ferrieri A et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dis Dis Sci 1999; 44 (6): 1220–1221. doi: 10.1023/a: 1026648812439.
9. Riegler R, Russo MI, Carratú R et al. Clinical and therapeutic considerations in the treatment of nonspecific abdominal disorders in patienst with quiescent ulcerative rectocolitis: preliminary notes on treatment with rifaximin. Eur Rev Med Pharmacol 1992; 14: 9–14.
10. Isaacs KL, Sandler RS, Abrue M et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2007; 13 (10): 1250–1255. doi: 10.1002/ibd.20187.
11. Shen B, Remzi FH, Lopez AR et al. Rifaximin for maintenance therapy in antibio­tic dependent pouchitis. BMC Gastroenterol 2008; 8: 26. doi: 10.1186/1471-230X-8-26.
12. Gionchetti P, Rizzello F, Venturi A et al. Antibio­tic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999; 13 (6): 713–718. doi: 10.1046/j.1365-2036.1999.00553.x.

Kreditovaný autodidaktický test